semaglutide+brands Off-brand Ozempic and Wegovy weight-loss drugs are a bad idea, FDA says Prescribing | Ozempic® (semaglutide) pill

Adverse events were predominantly mild gastrointestinal symptoms

Long-term use of GLP-1 medications may lead to a higher incidence of osteomalacia

A next generation GLP-3 triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously

FDA has agreed to the primary endpoint expected to be utilized in Phase 3 - Data from two Phase 2 studies of avexitide in people with PBH demonstrated highly statistically significant reductions in severe hypoglycemic events, an endpoint supported by the FDA - Avexitide was generally well tolerated, with a favorable safety profile replicated across five clinical trials in people with PBH - Management to host conference call and webcast today at

Poisoning reports linked to injectable weight-loss drugs nearly doubled in 2025, with experts warning over online and unsupervised use

Learn what to watch for and schedule a free consultation.